Participating in Web Summit Lisboa 2026
Expanding what is possible in cancer detection and monitoring.
DIASCI combines electrochemical biosensors with artificial intelligence to explore new ways of detecting and following aggressive cancers — a technology in development, open to partners who want to shape its next steps.
The challenge & the opportunity
Aggressive cancers demand new approaches to detection and follow-up.
Following how aggressive cancers evolve remains a scientific and clinical challenge. New, less invasive ways of reading biological signals could open room for better-informed decisions over time.
Where innovation fits
Combining biosensing and AI is an innovation path that DIASCI is building with research, intellectual property and regulatory planning — and one that investors, industry and institutions can help advance.
Context data
—
Incidence of aggressive cancers
Pending verified source
—
Current detection and monitoring gaps
Pending verified source
—
Addressable market
Pending verified source
DIONCO technology
From a blood sample to AI-supported interpretation.
A conceptual view of how the platform is designed to work. It describes the concept under development, not validated performance.
- 01
Blood sample
The analysis starts from a small blood sample.
- 02
Biomarker capture
The biosensor surface is designed to capture tumor-related biomarkers.
- 03
Electrochemical signal
Each capture event is converted into a measurable electrical signal.
- 04
AI-supported interpretation
AI models help interpret signal patterns together with other data.
In plain terms
Think of the biosensor as a highly selective listener: it reacts to specific molecules in the sample and turns that reaction into an electrical reading. The AI layer then looks for meaningful patterns in those readings — the kind of information that, once validated, could support detection and follow-up decisions.
Development hypotheses
Development hypothesis- Lower invasiveness than current approaches
- Faster turnaround of results
- Portability beyond central laboratories
These are goals under investigation, not demonstrated efficacy.
Technology Progress & Evidence
Early findings supporting new possibilities.
DIASCI is developing a platform that combines electrochemical biosensing and artificial intelligence to explore new approaches to the detection and monitoring of aggressive cancers. Company-reported preliminary studies inform further assessment and clinical validation.
Preliminary results
Company-reported findings from the evaluated assay. Figures will be published only after DIASCI's explicit approval.
AI platform development
AI models developed with patient data to interpret biosensor signals. Development data is not clinical validation.
Studies and validations
Scientific collaboration reported in the company portfolio; current stage to be confirmed.
Intellectual property
Patent applications in Brazil (INPI) and through the PCT system. Applications, not granted patents.
Next technology milestones
Strengthening evidence and completing the necessary validation steps.
Provisional content — to be replaced· Numerical results are under review and intentionally withheld from public display.
Scientific Foundations & Collaboration
Scientific foundations for what comes next.
DIASCI brings together expertise in biosensing, biotechnology and artificial intelligence, supported by applied research, innovation initiatives and scientific collaboration. These milestones reflect a structured development effort, while clinical and regulatory validation remains essential.
ANVISA regulatory pilot
Participation in ANVISA's pilot initiative for innovative medical devices under Public Call No. 10/2023.
Regulatory engagement — not a device registration or approval.
MCTI / RENAMA
Favorable technical assessment from Brazil's Ministry of Science, Technology and Innovation regarding DIASCI's application to join RENAMA.
A favorable opinion — formal membership still to be confirmed.
Research & scientific collaboration
Applied research and collaboration with scientific and clinical institutions.
Institutions named only after confirmation and authorization.
FAPESP & innovation initiatives
FAPESP PIPE support and innovation programs, as reported in the company portfolio.
Milestones and dates pending documentation.
Intellectual property
Patent applications in Brazil and through the international PCT system, a basis for licensing and co-development discussions.
Applications, not granted patents.
Institutional logos
Choose your opportunity
Six ways to take part in what comes next.
Each audience has its own entry point into DIASCI's technology.
Investors
Participate in the evolution of a health deep tech.
Explore an investment opportunityPharmaceutical Industry
Explore biomarker tracking and therapy-response monitoring, in development.
Discuss a pharmaceutical partnershipLaboratories
Evaluate potential new diagnostic services and future differentiation.
Explore laboratory opportunitiesClinics & Healthcare
Investigate future detection and oncology follow-up capabilities.
Explore clinical collaborationTechnology & Innovation
Connect biosensors, AI and clinical data.
Discuss a technology partnershipResearch Institutions
Advance joint research, validation and technology transfer.
Explore research collaborationDevelopment roadmap
From research to application: progress built step by step.
DIASCI is advancing its biosensing and AI technologies through intellectual property initiatives, scientific collaboration and regulatory planning.
Reported milestones
Date to be confirmed
Company foundation
Origins of DIASCI's research in biosensing and AI.
To be confirmedDate to be confirmed
Innovation programs
SUPERA Parque and FAPESP PIPE support, as reported in the company portfolio.
To be confirmedDate to be confirmed
Patent applications
Filing in Brazil (INPI BR 10 2023 025142-0) and international application PCT/BR2024/050213.
Patent applicationPublic Call 10/2023
ANVISA regulatory pilot
Participation in the pilot for innovative medical devices.
Regulatory participationAugust 2026
MCTI technical assessment
Favorable technical opinion regarding the RENAMA application.
Regulatory participation
Next steps
Upcoming
Evidence and validation
Strengthening evidence and completing the necessary validation steps.
Validation pendingUpcoming
Applications and partnerships
Structuring potential applications and partnerships with interested organizations.
Potential application
Team & clinical partners
The people behind the science.
The DIASCI team and the clinical partners who collaborate on its research.
DIASCI Team
Dr. Daniela S. Fernandes
CEO and Researcher
Dr. Cristiano C. Jayme
Researcher
Dr. Cláudia Razzino
Researcher
José Mario F. Donato
Business Consultant
Clinical Partners
Dr. Roger Chammas
Oncologist
Dr. Miyuki Uno
Biobank
Dr. Luciana Andrade
CTO, ICESP
Partners & Supporters
Join the next steps
Explore a future partnership with DIASCI.
Organizations and investors are invited to explore scientific collaboration, licensing, co-development, investment or future commercial applications, subject to the required technical, clinical and regulatory milestones.
Meeting requests
Online meeting requests will open soon. Meanwhile, choose your area above to learn more, or meet the DIASCI team at Web Summit Lisboa 2026.
Provisional content — to be replaced· Contact channel to be provided